Large-scale atrial fibrillation (AF) screening in the community is feasible with smartphone-based electrocardiography (ECG) performed by trained layperson volunteers, according to results of the AFinder programme in 11,574 citizens in Hong Kong.
Rivaroxaban in combination with aspirin significantly reduces cardiovascular (CV) death, stroke or MI vs aspirin alone in patients with stable cardiovascular disease (CVD), according to late-breaking results of the COMPASS trial presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain.
Late-breaking results from a multinational trial show for the first time that adding anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, to intensive statin therapy reduces cardiovascular (CV) events in high-risk patients, with the possibility of providing greater benefit with longer duration of treatment.
The anti-inflammatory agent canakinumab is found to reduce the risk of cardiovascular (CV) events in high-risk patients, providing proof of concept that inhibiting inflammation can improve CV outcomes independent of cholesterol levels.
Rivaroxaban in combination with aspirin has emerged as a potential new treatment option for patients with peripheral artery disease (PAD) as late-breaking results from the PAD cohort of the COMPASS trial show significantly reduced rates of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) compared with aspirin alone.
The practice of giving oxygen to patients with MI is challenged by a recent registry-based randomized clinical trial showing that this widely accepted practice does not improve survival, according to results presented at the European Society of Cardiology Congress 2017 (ESC 2017) held in Barcelona, Spain.
Blocking the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) with one to two injections of small interfering RNA (siRNA) provides sustained LDL-cholesterol (LDL-C) lowering for up to 1 year in patients with high cardiovascular (CV) risk and elevated LDL-C levels, the phase II ORION-1 study has shown.
Sildenafil should not be used to treat residual pulmonary hypertension in patients with corrected left valvular heart disease, according to the results of a late-breaking trial presented at the European Society of Cardiology (ESC) Congress 2017.
Renal denervation is efficacious in reducing blood pressure in adult patients with uncontrolled hypertension not taking any medications, according to late-breaking results from the SPYRAL HTN-OFF MED study presented at the European Society of Cardiology Congress 2017 (ESC 2017) held in Barcelona, Spain.
Late-breaking data presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain have shown that ibuprofen is associated with greater increase in blood pressure (BP) than celecoxib or naproxen in patients with arthritis, potentially increasing their risk of cardiovascular (CV) events. [Eur Heart J 2017, doi: 10.1093/eurheartj/ehx508]
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.